SBIR Phase I: Modular, Paper-based, Secured Diagnostics for Managing Viral Outbreaks (COVID-19)

SBIR 第一阶段：用于管理病毒爆发 (COVID-19) 的模块化、纸质、安全诊断

• 批准号: 2112144
• 负责人: Adam Carr
• 金额: $ 25.6万
• 依托单位: FRUGI BIOTECHNOLOGY INC.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-01 至 2022-07-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2112144&HistoricalAwards=false
• 关键词: SBIR; Phase; Modular; Paper; based

The broader impact of this Small Business Innovation Research (SBIR) Phase I Project is a cost-effective way to manage and track viral outbreaks in animal, human, and plant populations, including tracking for situations like the COVID-19 pandemic. It overcomes the challenges of current viral screening methods, namely PPE required for collecting samples, handling of samples to centralized analytic sites, cost of tests, and reliance on limited reagents. The platform proposed in this project could be used on-site at an animal production facility or at home. The scanner can be placed at many municipal and commercial locations (e.g., drug stores) or the envelope can be conveniently mailed for assessment. The dual read modality gives timely feedback to the client, as well as the capability for anonymous aggregation of readout data - essential for real-time tracking of viral outbreak and informing resource allocation to mitigate spread. This diagnostic platform would generate impact, allowing: 1) animal producers to mitigate virus spread and reduce loss and 2) businesses, schools, and other organizations to make real-time data-driven decisions on closures and health policies.The proposed project focuses on assessing technical feasibility of three critical elements of a diagnostic platform: (1) the ability to couple isothermal RNA amplification directly to cell-free extract using custom formulations, to simplify usability (eliminate current off-card amplification with commercial kits) and reduce cost; (2) Production of a scalable and efficient cell-free extract well-suited for amplification of reporter proteins by RNA circuits to increase the rate of protein production and reduced RNA degradation. The performance of this extract will inform the time to result as well as the cost of card, necessary metrics for translation; and (3) production of new toehold riboregulators (2 to 3) selective to virus targets relevant to the animal industry (e.g., swine flu, porcine respiratory). These will also inform the limits of detection. This project will evaluate the feasibility of such as system.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）I期项目的更广泛影响是一种经济高效的方式，可以管理和跟踪动物，人类和植物种群中的病毒爆发，包括跟踪Covid-19-19-19的大流行。 它克服了当前病毒筛查方法的挑战，即收集样品，将样品处理为集中分析地点，测试成本以及对有限试剂的依赖所需的PPE。 该项目中提出的平台可以在动物生产设施或家里现场使用。可以将扫描仪放置在许多市政和商业地点（例如，药店），也可以方便地邮寄信封进行评估。双重读取方式及时向客户端提供反馈，以及匿名读数数据匿名聚合的功能 - 对病毒爆发的实时跟踪至关重要，并告知资源分配以减轻差异。 This diagnostic platform would generate impact, allowing: 1) animal producers to mitigate virus spread and reduce loss and 2) businesses, schools, and other organizations to make real-time data-driven decisions on closures and health policies.The proposed project focuses on assessing technical feasibility of three critical elements of a diagnostic platform: (1) the ability to couple isothermal RNA amplification directly to cell-free extract using custom formulations, to simplify usability （消除使用商业套件的当前放大现金放大）并降低成本； （2）生产可扩展有效的无细胞提取物，非常适合通过RNA回路扩增报告基因蛋白，以提高蛋白质产生的速率并降低RNA降解。 该提取物的性能将为您的结果和卡的成本，需要翻译的必要指标提供信息； （3）生产新的脚趾骨调节剂（2至3）选择与动物工业相关的病毒靶标（例如猪流感，猪呼吸道）。 这些也将为检测的限制提供信息。 该项目将评估诸如系统之类的可行性。该奖项反映了NSF的法定任务，并使用基金会的知识分子优点和更广泛的影响审查标准，被认为值得通过评估获得支持。